Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 17, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Expert viewpoint on endpoints in systemic sclerosis: current and future outlook.

Anna-Maria Hoffmann-Vold1,2, Oliver Distler2, Francesco Del Galdo3

  • 1Department of Rheumatology, Oslo University Hospital, Oslo, Norway.

RMD Open
|July 15, 2026
PubMed

Related Concept Videos

Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and safety of riociguat in early pulmonary vascular disease (ESRA): a prospective, multicenter, randomized, double-blind, placebo-controlled phase IIa trial.

Chest·2026
Same author

Multicentre international audit of IMACS malignancy screening guidelines in idiopathic inflammatory myopathies: insights from the myositis audit and research collaborative group.

RMD open·2026
Same author

Critical ischemia of multiple organ systems in a patient with systemic lupus erythematosus complicated by catastrophic antiphospholipid syndrome: Potential pathogenetic role of non-inhibitory anti-ADAMTS13 autoantibodies.

Modern rheumatology case reports·2026
Same author

Site-specific articular responses to b/tsDMARDs in rheumatoid arthritis: a longitudinal observational study from the Swiss Clinical Quality Management Registry.

RMD open·2026
Same author

Expert recommendations for the management of fecal incontinence in systemic sclerosis: A report from the World Scleroderma Foundation (WSF) Gastrointestinal "Ad hoc committee".

Journal of scleroderma and related disorders·2026
Same author

Expert recommendations for the management of refractory gastroesophageal reflux disease in systemic sclerosis: A report from the World Scleroderma Foundation (WSF) Gastrointestinal "Ad hoc committee".

Journal of scleroderma and related disorders·2026
Summary

Systemic sclerosis (SSc) clinical trials need better endpoints. Patient-reported outcomes and composite measures are improving trial design, but earlier detection and broader assessments are crucial for therapeutic development.

Area of Science:

  • Rheumatology
  • Clinical Trial Design
  • Autoimmune Diseases

Background:

  • Systemic sclerosis (SSc) is a complex autoimmune disease with varied organ involvement.
  • Clinical trial design for SSc faces challenges due to disease heterogeneity.
  • Historical trial concepts include single-organ, supportive secondary, and combined endpoints.

Purpose of the Study:

  • To review the current landscape of clinical endpoints in Systemic Sclerosis trials.
  • To explore future directions and unmet needs in SSc clinical endpoint selection.
  • To discuss the integration of patient-reported outcomes and composite endpoints.

Main Methods:

  • Expert review of existing literature and trial methodologies in Systemic Sclerosis.
  • Analysis of the role of patient-reported outcomes (e.g., HAQ-DI, ScleroID).
Keywords:
BiomarkersClinical TrialHealth-Related Quality Of LifePatient Reported Outcome MeasuresScleroderma, Systemic

Related Experiment Videos

Last Updated: Jul 17, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

  • Evaluation of candidate composite endpoints (e.g., CRISS) and their components.

    • Main Results:

    • Patient-reported outcomes offer valuable insights into patient experience.
    • Composite endpoints like the revised CRISS integrate diverse measures for efficacy assessment.
    • Current endpoints often assess damage at late stages, highlighting a need for early indicators.

    Conclusions:

    • Refining composite endpoints to include continuous measures and broader domains (vascular, GI) is essential.
    • Incorporating time-to-event analyses, imaging, and biomarkers will enhance trial sensitivity.
    • Improved endpoint selection is critical for advancing therapeutic development and patient outcomes in SSc.